About HTAsiaLink

The Network To Strengthen Collaboration Among HTA Agencies In Asia

What is HTAsiaLink

Network for HTA research and evidence-based policy in Asia Pacific

HTAsiaLink is a network of organizational and individual members who are involved in HTA research and evidence-based policy decision-making in Asia and Pacific region. Organizational members include HTA institutions, government HTA units, and other relevant organizations. Individual members include researchers, academics, and professionals in the field of HTA.

Since its establishment in 2011 by the three founding members: Thailand’s Health Intervention and Technology Assessment Program, South Korea’s National Evidence-Based Healthcare Collaborating Agency, and Taiwan’s Center for Drug Evaluation, the network has grown in size and geographical breadth. Its key event is an annual conference held in different host countries, to bring together members for networking, sharing of research findings, and collaborative discussions.

HTAsiaLink serves as a platform for knowledge transfer and exchange related to evidence-based priority setting, with the main objective of enhancing the capacity for HTA research and promoting the integration of HTA evidence into policy decisions. The network was formed to address the need for strengthening HTA capacity in Asia and promoting the use of HTA evidence in policy decisions.

Healthcare Vision
Our Vision

The Future We Are Building

Welcome to the first HTAsiaLink Strategic Plan for 2025-2030 – a shared roadmap for strengthening and advancing the future of Health Technology Assessment (HTA) across the Asia-Pacific region.
With HTAsiaLink’s continued expansion, this strategic plan provides a clear roadmap to guide our shared commitment to evidence-informed policymaking, regional collaboration, and inclusive growth through strategic direction and well-defined actions.

  • This plan is structured into three main sections:

    • Strategic Goals: Outlines direction for the network’s efforts to support its members in the next five years
    • Path Forward: Details the initiatives and actions HTAsiaLink will pursue to achieve its strategic goals, providing a clear implementation roadmap.
    • Impact Measures: Defines measurable indicators to track progress, ensure accountability, and demonstrate value to members and stakeholders.

    The HTAsiaLink Strategic Plan is not just a roadmap, it is a call to action. We encourage you to engage with the plan and contribute to advancing HTA for better health outcomes across Asia-Pacific regions.

Learn More

Board of Directors

Ms. Ling-Chen (Cathy) Chien
Ms. Ling-Chen (Cathy) Chien

President

CDE

Prof. apt. Auliya A. Suwantika
Prof. apt. Auliya A. Suwantika

Vice President

InaHTAC

Mr. Benjamin Ong
Mr. Benjamin Ong

Member

ACE

Dr. Izzuna Mudla Mohamed Ghazali
Dr. Izzuna Mudla Mohamed Ghazali

Member

MaHTAS

Dr. Miyoung Choi
Dr. Miyoung Choi

Member

NECA

Dr. Sitanshu Sekhar Kar
Dr. Sitanshu Sekhar Kar

Member

JIPMER

Dr. Takashi Fukuda
Dr. Takashi Fukuda

Member

C2H, NIPH

Prof. Wendy Babidge
Prof. Wendy Babidge

Member

ASERNIP-S

HTAsiaLink Secretariat

HTAsiaLink Transition Secretariat Team
Center for Drug Evaluation (CDE)

Office Location
3F No.465, Sec.6, Zhongxiao E. Rd., Taipei 11557, Taiwan. R.O.C.
Secretariat Office